UPDATE : Wednesday, December 11, 2019
상단여백
Aprogen, 1st Korean biotech firm to win unicorn status by Jeong Sae-im 2019-12-11 13:10
Samsung Bioepis to start P3 trial for Ontruzant in China by Lee Han-soo 2019-12-10 14:16
Samsung execs get jail term for destroying evidence by Jeong Sae-im 2019-12-10 11:43
Celltrion unveils long-term P3 trial results for Truxima in US by Lee Han-soo 2019-12-09 10:36
Celltrion 1st Korean biopharmaceutical firm to achieve $1-billion exports by Lee Han-soo 2019-12-05 15:04
라인
Alteogen inks licensing-out deal for SC injection formulation technology by Jeong Sae-im 2019-12-02 15:25
Kolon Life Science’s research head arrested for false Invossa data by Jeong Sae-im 2019-11-28 11:18
FDA begins to review Samsung Bioepis' anticancer biosimilar application by Lee Han-soo 2019-11-20 15:10
Vivozon’s acquisition of Lumimicro may aim at backdoor listing by Jeong Sae-im 2019-11-20 14:44
ABL Bio, Genscript to cooperate on bispecific antibodies by Lee Han-soo 2019-11-19 17:18
라인
Will Biogen be 1st to get FDA nod for Alzheimer’s drug? by Kim Yun-mi 2019-11-14 11:23
How can Korean drugmakers enter Europe successfully? by Jeong Sae-im 2019-11-13 15:22
Samsung Bioepis expects ₩1 trillion biosimilar sales this year by Jeong Sae-im 2019-11-13 15:21
[News Focus] ‘FDA could allow resumption of Invossa trial’ by Jeong Sae-im 2019-11-12 15:48
Celltrion marks robust Q3 sales by Lee Han-soo 2019-11-07 14:03
라인
Samsung Bioepis, Biogen to commercialize next-generation biosimilar candidates by Lee Han-soo 2019-11-07 11:16
Court rejects arrest warrant for 2 Kolon execs by Jeong Sae-im 2019-11-05 13:54
Samsung BioLogics to make Ichnos Sciences’ atopic dermatitis treatment by Lee Han-soo 2019-11-05 12:47
Prosecutors seek to arrest 2 Kolon execs for false Invossa data by Jeong Sae-im 2019-10-31 15:34
Syntekabio passes prior review for Kosdaq listing by Jeong Sae-im 2019-10-31 13:27
여백
여백
여백
Back to Top